An elderly advanced non-small cell lung cancer patient harboring rare epidermal growth factor receptor mutations L861R benefited from afatinib: A case report

RATIONALE: Tyrosine kinase inhibitors (TKIs) have significant efficacy in patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. No clear evidence exists that EGFR-L861R is sensitive to TKIs, and the best treatment for NSCLC patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Fanjie, Wu, Shuang, Dong, Huacheng, Yan, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589233/
https://www.ncbi.nlm.nih.gov/pubmed/34766562
http://dx.doi.org/10.1097/MD.0000000000027614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589233/
https://www.ncbi.nlm.nih.gov/pubmed/34766562
http://dx.doi.org/10.1097/MD.0000000000027614

Ejemplares similares